Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
Sight Sciences
SGHT
Sight Sciences
Restrictive Reimbursement Will Undermine Ophthalmic Margins While Slow Recovery Emerges
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
13 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$3.60
16.7% overvalued
intrinsic discount
16 Aug
US$4.20
Loading
1Y
-30.6%
7D
-0.9%
Author's Valuation
US$3.6
16.7% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$3.6
16.7% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-80m
86m
2018
2020
2022
2024
2025
2026
2028
Revenue US$86.1m
Earnings US$10.7m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
10.08%
Medical Equipment revenue growth rate
0.45%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.89%
Calculation
US$10.69m
Earnings '28
x
24.95x
PE Ratio '28
=
US$266.72m
Market Cap '28
US$266.72m
Market Cap '28
/
59.07m
No. shares '28
=
US$4.52
Share Price '28
US$4.52
Share Price '28
Discounted to 2025 @ 7.89% p.a.
=
US$3.60
Fair Value '25
